The conversation is about seeking alternatives to finasteride for hair loss treatment due to concerns about sexual side effects, with pyrilutamide mentioned as a potential alternative.
The conversation discusses the high cost of CB-03-01, a topical antiandrogen for hair loss, which is considered safe and remains localized upon application. It questions whether the expense is justified compared to the lower risks it poses relative to finasteride.
The user is hesitant to use finasteride due to potential hormonal side effects and is waiting for the release of pyrilutamide, a new hair loss treatment. Other users suggest trying finasteride, warning about potential regret if hair loss progresses in the meantime.
KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.
The conversation discusses topical androgen receptor blockers for hair loss, mentioning Clascoterone, Pyrilutamide, GT20029, and RU58841. Ketoconazole's effectiveness and application methods are also debated.
Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.
Hair cloning is humorously discussed as always being 5-7 years away, with skepticism about its near-term availability. Gene editing to reactivate dormant follicles is suggested as a more likely solution within the next ten years.
The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.
A 57-year-old man shared his 6-month hair regrowth progress using RU58841, Minoxidil, microneedling, and Nizoral. He experienced significant improvement, with a smaller bald spot, thicker hair, and hairline regrowth.
A user received Kintor’s KX-826/Pyrilutamide and shared initial impressions, noting concerns about the product's labeling and marketing. Other users discussed the legitimacy of the product, its effectiveness, and compared it to other treatments like Minoxidil and Finasteride.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
Female with aga tried minoxidil 5% and spironolactone, no success yet. Gladyator96 suggests waiting 6 months, adding tretinoin or dermarolling with minoxidil.
A PhaseII clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.
The conversation discusses the comparison of Pyrilutamide PhaseII US trial results with 1 mg finasteride for hair loss treatment. It mentions that the total hair count increase in the US trial was not as good as the China trial.
Kintor Pharma completed a successful PhaseII clinical trial for KX-826, a treatment for androgenetic alopecia. KX-826 is similar to finasteride with minor side effects and is more backed than Cosmerna.
KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phaseII clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into PhaseIII trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.
Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.
The conversation discusses disappointment with the hair loss treatment KX-826 but notes that the company Kintor is still focused on developing and commercializing it, as stated in their 2023 annual report. The user questions the effectiveness of KX-826 in comparison to minoxidil's role in improving hair thickness and appearance.
Users discuss aggressive promotion of Koshine 826, suspecting Kintor employees are behind it. Concerns are raised about its effectiveness, with some preferring alternatives like finasteride and minoxidil.
Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.
Guyman567 has been using oral finasteride and topical minoxidil for years but continues to experience hair loss and thinning, which has affected his confidence. He has tried various treatments including topical finasteride, microneedling, and vitamins, and is considering a hair transplant but is concerned about ongoing hair loss.
Breezula protects hair follicles from both testosterone and DHT, unlike finasteride, which only protects against DHT. This could potentially lead to significant hair regrowth, similar to results seen in transgender individuals using hormone blockers.
A male with early-stage hair loss experienced severe side effects, including sexual dysfunction from finasteride and increased heart rate and fatigue from high-dose minoxidil, leading to discontinuation of both treatments. He is now relying on DHT-blocking shampoos and awaiting new treatments.
Kintor's Pyrilutamide results for hair loss treatment will be released soon. The treatment may replace current treatments like finasteride and minoxidil without systemic side effects.
The conversation discusses the effectiveness of reducing DHT for hair loss treatment and explores alternative approaches like reducing androgen receptor sensitivity. Specific treatments mentioned include finasteride, dutasteride, pyrilutamide (KX-826), GT20029, and RU58841.